| Literature DB >> 17549239 |
Abstract
Clinical testing of the nutraceuticals glucosamine (glcN) and chondroitin sulfate (CS) has shown efficacy in providing relief from symptoms in osteoarthritic patients. In vitro and in vivo studies support existence of a synergistic relationship upregulating synthetic activity in chondrocytes. A combination of glcN and CS may also be useful as adjunct therapy in sports-related injuries if similar upregulation of collagen synthesis is elicited in accessory ligament and tendon joint tissue. Collagen and non-collagenous protein (NCP) synthesis in cultures of bovine tenocytes, ligament cells and chondrocytes exposed to glcN + CS were assayed by uptake of radiolabeled proline into collagenase-sensitive material. Assay of radiolabel in hydroxyproline (a specific marker for collagen synthesis) following HPLC isolation confirmed the specificity of the metabolic effect. Synthesis of total collagenase-sensitive material was maximally upregulated at physiologically obtainable doses of glcN + CS. Tissue response followed the sequence ligament cells (+69%) > chondrocytes (+56%) > tenocytes (+22%). Labeled hydroxyproline increased by 132% in ligament cells, 27% in tenocytes and 49% in epitendon cells after a 48 h exposure to 5 mug ml(-1) glcN + 4 mug ml(-1) CS. Low dose combinations of glcN and CS effectively stimulate in vitro collagen and NCP synthesis by ligament cells, tenocytes and chondrocytes. Hence, therapeutic use following accessory joint tissue trauma may help augment repair processes.Entities:
Year: 2006 PMID: 17549239 PMCID: PMC1876619 DOI: 10.1093/ecam/nel081
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Collagen synthesis by chondrocytes, ligament cells and tenocytes exposed to varying doses of CDS
| Control | IGF (50 ng ml−1) | CDS (1 µg ml−1) | CDS (10 µg ml−1) | CDS (50 µg ml−1) | CDS (100 µg ml−1) | |
|---|---|---|---|---|---|---|
| Chondrocytes | 380 (60) | 600 (96)† | 592 (112)† | 560 (60)† | 580 (112) | 352 (58) |
| Ligament Cells | 520 (32) | 944 (132)† | 880 (120)† | 920 (148)† | 656 (120) | 576 (56) |
| Tenocytes | 316 (43) | 460 (35)† | 385 (35)† | 419 (30)† | 364 (45) | 345 (43) |
Data presented as Mean (±SEM) (n = 8) CPM tritiated proline uptake into collagenase-sensitive material (collagen).
†Denotes statistical significance at P < 0.05 to 0.001.
Comparative analysis of hydroxyproline and proline-specific activity in collagen of connective tissue cells exposed to CDS and IGF-1
| Assay | Ligament | Tendon | Epitendon | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | CDS | IGF | Control | CDS | IGF | Control | CDS | IGF | |
| SA Hyp | 68 (13) | 158† (35) | 195† (38) | 250 (23) | 318† (25) | 626† (120) | 378 (45) | 563† (120) | 740† (160) |
| SA Pro | 120 (26) | 196† (25) | 348† (69) | 230 (35) | 326† (45) | 555† (110) | 180 (24) | 167 (28) | 300† (55) |
Data given as Mean (±SEM) specific activity (cpm hyp μg−1 hyp and cpm pro μg−1 pro) in cultures exposed to agents for 48 h.
†Indicates values statistically significant from control value at P < 0.05.
Ratio of labeled proline in collagen to labeled proline in NCP
| Chondrocytes | Tenocytes | Ligament cells | |
|---|---|---|---|
| Control | 1.09 (0.12) | 0.72 (0.11) | 0.90 (0.08) |
| CDS | 0.80 (0.04) | 1.06 (0.10) | 0.97 (0.25) |
| IGF-1 | 3.15 (0.66)† | 2.15 (0.55)† | 0.83 (0.20) |
Data expressed as ratio of CPM (±SEM) of labeled proline in collagen versus labeled proline in NCP.
†Indicates statistically significant at P < 0.05.
Figure 1.CS + GlcN represents increased collagen synthesis and Trauma/Stress represents collagen synthesis.